Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "Basel"

110 News Found

U.S. FDA approves drug-free VNS system for stroke
Drug Approval | August 28, 2021

U.S. FDA approves drug-free VNS system for stroke

When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke


Lonza to establish manufacturing facility in Guangzhou, China
News | August 25, 2021

Lonza to establish manufacturing facility in Guangzhou, China

The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services


US FDA approves Jardiance to treat adults living with heart failure with a reduced ejection fraction
Drug Approval | August 20, 2021

US FDA approves Jardiance to treat adults living with heart failure with a reduced ejection fraction

New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US


Novartis announces positive results from Phase 3 trials of Beovu for diabetes
Drug Approval | August 18, 2021

Novartis announces positive results from Phase 3 trials of Beovu for diabetes

Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one


Novatek Pharma initiates Phase II study of oral COVID-19 drug
Drug Approval | August 14, 2021

Novatek Pharma initiates Phase II study of oral COVID-19 drug

This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants


GW Pharmaceuticals receives approval for Epidyolex to treat seizures
Drug Approval | August 11, 2021

GW Pharmaceuticals receives approval for Epidyolex to treat seizures

TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines


Glenmark's interim data from PMS Study on Favipiravir released
News | June 09, 2021

Glenmark's interim data from PMS Study on Favipiravir released

The study was conducted in patients with mild to moderate COVID-19


Merck publishes sustainability report for 2020
News | April 13, 2021

Merck publishes sustainability report for 2020

The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.


COVAXIN demonstrates interim clinical efficacy of 81%
News | March 04, 2021

COVAXIN demonstrates interim clinical efficacy of 81%

Bharat Biotech expects to share further details of the trial results as additional data become available.


Merck FY20 sales up 8.6% euro 17.5 bn
News | March 04, 2021

Merck FY20 sales up 8.6% euro 17.5 bn

Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.